In the NCT03608618 trial evaluating MCY-M11, intraperitoneal administration of anti-mesothelin CAR-Ms led to disease stabilization in a subset of patients with advanced ovarian cancer and malignant peritoneal mesothelioma, with stable disease observed in several patients after a single treatment cycle. The gene discussed is MSLN; the disease is ovarian carcinoma.